Abstract | OBJECTIVES: METHODS: RESULTS: Seventeen cases of non-typhi Salmonella infection were observed in the series of patients exposed to anti- TNF-alpha therapies. The incidence rate of non-typhi Salmonella in BIOBADASER was 0.73 per 1000 patient-years (95% confidence interval [CI]: 0.45-1.17). The incidence rate in the EMECAR cohort was 0.44 per 1000 patient-years. The relative risk for non-typhi salmonellosis in RA patients exposed to TNF-alpha inhibitors compared to those not treated with biological therapies was 2.07 (95% CI: 0.27-15.73) (p=0.480) whereas the relative risk of non-typhi Salmonella infections in patients with rheumatic diseases undergoing TNF-alpha antagonist therapy compared with the non-RA Spanish control cohort was 0.63 (95% CI: 0.38-1.04) (p=0.07). Nine of the 17 patients with non-typhi salmonellosis presented a severe systemic infection. CONCLUSION:
|
Authors | J L Peña-Sagredo, M C Fariñas, B Perez-Zafrilla, A Cruz-Valenciano, M Crespo, B Joven-Ibañez, E Riera, F J Manero-Ruiz, I Chalmeta, M V Hernández, M Rodríguez-Gómez, O Maíz, R López, T Cobo, J Pita, L Carmona, M A Gonzalez-Gay, BIOBADASER and EMECAR Groups |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
2009 Nov-Dec
Vol. 27
Issue 6
Pg. 920-5
ISSN: 0392-856X [Print] Italy |
PMID | 20149306
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Female
- Humans
- Immunotherapy
- Incidence
- Male
- Middle Aged
- Registries
- Rheumatic Diseases
(complications, epidemiology, therapy)
- Salmonella Infections
(complications, epidemiology)
- Spain
(epidemiology)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, therapeutic use)
|